Does Blue Cross Blue Shield Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), a protein essential for osteoclast formation and survival. By blocking RANKL, denosumab slows bone resorption and increases bone mineral density. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high risk of fracture, and the indication later expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients on certain cancer therapies. [1]

Clinical Evidence Supporting Coverage

The FREEDOM trial enrolled 7,808 postmenopausal women aged 60 to 90 with a femoral neck T-score between -2.5 and -4.0. At 36 months, subcutaneous denosumab 60 mg every 6 months reduced new vertebral fractures by 68% relative to placebo (7.2% vs. 2.3%, P<0.001) and hip fractures by 40% (P<0.05). [2] These numbers are the backbone of every BCBS medical necessity argument you will make during prior authorization.

The FREEDOM Extension followed participants for a total of 10 years. Lumbar spine bone mineral density continued to increase through year 10, reaching a mean gain of 21.7% from baseline. [3] Sustained efficacy data matter because insurers sometimes question long-term renewal of coverage.

FDA-Approved Indications Relevant to Coverage

Prolia carries FDA approval for six distinct indications. [1] Each indication may map to a different ICD-10 code, and submitting the wrong code is one of the most common reasons a prior authorization request is denied before clinical review even begins. The six indications are:

• Postmenopausal women with osteoporosis at high fracture risk (M81.0)
• Men with osteoporosis at high fracture risk (M81.8)
• Glucocorticoid-induced osteoporosis (M81.6)
• Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer
• Giant cell tumor of the bone (different dosing regimen; covered under oncology benefits)

Matching the correct ICD-10 code to the correct FDA indication is a simple step that can prevent an automatic administrative denial.

How Blue Cross Blue Shield Plans Are Organized

BCBS is not a single insurer. It is a federation of 34 independent regional affiliates licensed by the Blue Cross Blue Shield Association. [4] Coverage rules, formulary tiers, and prior authorization criteria differ by affiliate and by the specific plan a member holds within that affiliate.

Commercial Fully Insured Plans

Fully insured commercial plans sold directly by a BCBS affiliate follow that affiliate's drug formulary. Prolia almost universally lands on a specialty tier (Tier 4 or Tier 5), which carries the highest cost-sharing. Coinsurance of 20 to 40% per injection is typical, meaning a member could owe $360 to $720 per injection (roughly $720 to $1,440 per year) even after the plan pays its share, assuming a negotiated rate near $1,800 per dose.

Self-Funded Employer Plans Administered by BCBS

Self-funded plans are designed by the employer, not the insurer. BCBS acts only as the claims processor. These plans can have entirely different formularies, different prior authorization criteria, and different cost-sharing structures. Members on self-funded plans should request a copy of the Summary Plan Description and the applicable drug formulary directly from their HR benefits department to verify Prolia's tier and criteria.

Medicare Advantage Plans

BCBS Medicare Advantage plans cover Prolia under the medical benefit (Part B equivalent) when a physician administers the injection in an office or outpatient clinic. [5] When a patient self-administers (rare for Prolia but technically possible), the drug may fall under Part D instead. Most BCBS Medicare Advantage plans follow CMS's National Coverage Determination framework for osteoporosis drug therapy. [6]

Medicaid Managed Care Plans

Several BCBS affiliates operate Medicaid managed care organizations in their states. These plans follow state Medicaid preferred drug lists (PDLs). Coverage and prior authorization criteria vary by state. Contact your state's Medicaid program or the BCBS Medicaid plan directly for current PDL status.

Prior Authorization: What BCBS Typically Requires

Prior authorization (PA) is nearly universal for Prolia on BCBS plans. The good news is that the PA criteria are predictable. Most affiliates publish their coverage policies online; the language below reflects common elements seen across multiple BCBS affiliate medical policies as of 2024.

Standard Clinical Criteria

A typical BCBS PA for Prolia requires documentation of all of the following:

1. A DXA (dual-energy X-ray absorptiometry) scan confirming a T-score at or below -2.5 at the lumbar spine or femoral neck, OR a documented low-trauma fracture. The National Osteoporosis Foundation guidelines define "high risk" as a FRAX 10-year probability of major osteoporotic fracture at or above 20%, or hip fracture probability at or above 3%. [7]
2. A trial of an oral bisphosphonate (alendronate, risedronate, or ibandronate) of at least 3 to 6 months, OR documented contraindication, intolerance, or failure of bisphosphonate therapy.
3. A current prescription from a physician (MD or DO), nurse practitioner, or physician assistant with prescribing authority.
4. Confirmation that the patient is not pregnant and does not have hypocalcemia. [1]

Lab Values That Can Block Approval

Denosumab is contraindicated in hypocalcemia. [1] BCBS plans routinely require a serum calcium level drawn within 30 to 90 days of the PA request. Correcting hypocalcemia before submitting the PA request avoids a medically unnecessary denial. Vitamin D insufficiency (25-OH-D below 30 ng/mL) should also be addressed; the Endocrine Society's 2011 clinical practice guideline recommends supplementation to maintain levels above 30 ng/mL in patients receiving bone-active therapy. [8]

Renewal Authorization

Prolia is administered every 6 months. Most BCBS plans require renewal PA every 12 months (two injections). Renewal typically requires documentation of ongoing clinical benefit, defined as stable or improved bone mineral density on repeat DXA, or absence of new low-trauma fractures that would suggest treatment failure. Missing a renewal window can cause a coverage lapse and a gap in therapy, which is clinically significant: abrupt discontinuation of denosumab is associated with rapid bone mineral density loss and rebound vertebral fractures, as documented in a 2017 case series in the Journal of Bone and Mineral Research. [9]

Medicare Part B Coverage for Prolia

For patients 65 and older enrolled in traditional Medicare or a BCBS Medicare Advantage plan, Prolia is almost always covered under Part B rather than Part D. The Centers for Medicare and Medicaid Services (CMS) classifies physician-administered injectables as Part B drugs. [5] Under Part B, after the annual deductible ($257 in 2025), Medicare pays 80% of the Medicare-approved amount and the patient owes 20%. For BCBS Medicare Advantage members, the plan's cost-sharing schedule applies instead.

The 2024 Medicare Part B average sales price (ASP) for denosumab 60 mg (J0897) was approximately $1,087, making the 20% coinsurance roughly $217 per injection for traditional Medicare beneficiaries who have met their deductible. [10] Medicare Supplement (Medigap) plans typically cover most or all of that 20% coinsurance.

CMS National Coverage Determination 150.3 covers injectable osteoporosis drugs, including denosumab, for beneficiaries who have a bone fracture related to postmenopausal osteoporosis and are unable to self-administer the injection. [6] For patients who do not meet the fracture criterion, coverage flows through the Medicare Advantage plan's own medical policy.

Navigating a Prior Authorization Denial

Denials happen. The most common reasons for an initial PA denial for Prolia under a BCBS plan are:

• Incomplete clinical documentation (missing DXA report or FRAX score)
• No documented bisphosphonate trial or clearly stated contraindication
• Incorrect ICD-10 code on the PA request
• Missing lab values (serum calcium)
• Submission by office staff unfamiliar with the specific affiliate's PA form

The Appeals Process, Step by Step

Every BCBS plan is required by federal law to provide at least one level of internal appeal and, in most cases, access to external independent review. [11] The general sequence is:

1. Request the denial letter in writing. It must state the specific clinical reason for denial and cite the plan's coverage policy.
2. File a Level 1 internal appeal within the stated deadline. Most plans allow 180 days from the denial date for non-urgent appeals.
3. Submit a complete clinical package. Include the DXA report with T-scores, the treating physician's letter of medical necessity, documentation of bisphosphonate trial or contraindication, relevant lab values, and citations from peer-reviewed literature or clinical guidelines. The AACE/ACE 2020 clinical practice guidelines for osteoporosis management list denosumab as a Category A recommendation for high-risk patients. [12]
4. Request a peer-to-peer review. The treating physician can often speak directly with the BCBS medical director reviewing the case. This conversation resolves many Level 1 appeals without escalation.
5. File a Level 2 appeal or request external review if the Level 1 appeal is denied. External independent review organizations (IROs) overturn insurer decisions at meaningful rates, particularly when the clinical evidence is strong.

What the Data Say About Appeal Success

An analysis of insurer denial and appeal data published in Health Affairs found that patients who appeal health insurance denials succeed roughly 39 to 59% of the time depending on plan type and clinical indication. [13] For drugs with strong guideline endorsement, such as denosumab for high-risk osteoporosis, appeal success rates trend toward the higher end of that range when documentation is thorough.

Cost Assistance Programs When Coverage Falls Short

Even with insurance, out-of-pocket costs for Prolia can be substantial. Several assistance pathways exist.

Amgen Prolia360

Amgen operates a comprehensive support program called Prolia360. Commercially insured patients who qualify may receive a copay card reducing their out-of-pocket cost to as little as $0 per injection. The program also offers a patient assistance program (PAP) for uninsured or underinsured patients who meet income criteria. The Prolia360 enrollment line is 1-800-772-6436. Medicare beneficiaries are not eligible for copay cards under federal anti-kickback guidance, but may qualify for the PAP based on income. [14]

State Pharmaceutical Assistance Programs

Several states operate pharmaceutical assistance programs for seniors and low-income residents. The Medicare Rights Center maintains a state-by-state directory of these programs. [15] Eligibility criteria and benefit amounts vary widely by state.

The Extra Help / Low Income Subsidy Program

Medicare beneficiaries with limited income and resources may qualify for the Medicare Part D Extra Help program (also called the Low Income Subsidy, or LIS). For beneficiaries whose Prolia is billed under Part D rather than Part B, Extra Help can dramatically reduce cost-sharing. The Social Security Administration administers the program; eligibility is based on income at or below 150% of the federal poverty level. [16]

Clinical Context: Why Prolia Coverage Matters

Osteoporosis affects an estimated 10.2 million adults in the United States, with an additional 43.4 million classified as having low bone mass, according to data from the National Osteoporosis Foundation. [7] The 10-year probability of a hip fracture in a 70-year-old woman with a femoral neck T-score of -2.5 is approximately 8 to 10% using the FRAX algorithm. [17] Hip fractures carry a one-year mortality rate of approximately 21 to 23% in patients over age 65. [18]

Denosumab vs. Oral Bisphosphonates: When Prolia Is Clinically Indicated

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) remain the first-line agents in most guidelines because of their long safety record, generic availability, and low cost. The 2022 American College of Physicians guidelines recommend pharmacologic treatment for women 65 and older with osteoporosis (T-score at or below -2.5) to reduce fracture risk. [19] Denosumab moves to the front of the prescribing decision in several specific clinical scenarios:

• Chronic kidney disease stage 3b or worse, where bisphosphonate use requires dose adjustment or avoidance
• Documented esophageal disease or inability to remain upright for 30 to 60 minutes after taking an oral medication
• Prior bisphosphonate failure (continued bone loss or fracture on therapy)
• Need for subcutaneous rather than oral administration due to GI comorbidity

A 2023 network meta-analysis in The Lancet comparing 20 osteoporosis drugs found that denosumab ranked among the top three agents for reducing vertebral fracture risk in postmenopausal women, with an odds ratio of 0.27 (95% CI 0.20 to 0.37) vs. Placebo. [20] That quantitative ranking can be included in a letter of medical necessity when appealing a denial.

Glucocorticoid-Induced Osteoporosis: A Frequently Overlooked Indication

Long-term glucocorticoid use (prednisone 5 mg/day or more for 3 months or longer) is the most common cause of secondary osteoporosis. The American College of Rheumatology 2022 guidelines for prevention and treatment of glucocorticoid-induced osteoporosis conditionally recommend denosumab as an alternative to bisphosphonates for patients at high or very high fracture risk. [21] This indication is FDA-approved, which means BCBS plans that list Prolia on their formulary cannot deny coverage solely on the basis that oral agents are available, provided the clinical criteria in the plan's coverage policy are met.

How to Submit a Successful Prior Authorization the First Time

Submitting a complete, well-documented PA request is the single most effective way to avoid delays. The checklist below reflects the documentation that satisfies the criteria in most BCBS affiliate PA policies.

PA Documentation Checklist

• DXA scan report with numeric T-scores at lumbar spine (L1-L4) and femoral neck, dated within 24 months
• Calculated FRAX score (available at sheffield.ac.uk/FRAX) with the femoral neck BMD entered for maximum accuracy
• Documented bisphosphonate trial of at least 3 to 6 months, with dates and drug name, OR a written statement of contraindication or intolerance with clinical rationale
• Serum calcium and serum 25-OH-D levels drawn within 90 days
• Confirmed absence of pregnancy in women of childbearing potential (denosumab is Pregnancy Category X equivalent under current FDA labeling) [1]
• ICD-10 code matching the specific FDA-approved indication
• Letter of medical necessity from the prescribing clinician referencing the FREEDOM trial data and applicable AACE/ACE or ACP guideline recommendation

Submitting all of these documents in the initial PA request, rather than responding to piecemeal requests for additional information, reduces average PA turnaround time and limits opportunities for administrative denial.

Key Takeaways for Patients and Prescribers

BCBS does cover Prolia. The path to coverage is predictable when the clinical documentation is complete. The most avoidable reasons for denial are missing DXA data, absent documentation of bisphosphonate history, and incorrect billing codes.

For prescribers, matching the clinical scenario to the FDA-approved indication, submitting all lab values upfront, and being available for a peer-to-peer call will resolve the majority of cases at the initial PA stage. For patients, understanding the appeal process and the availability of Amgen's Prolia360 program means that a first denial does not have to mean an extended gap in therapy.

Per the FREEDOM trial, a single missed injection carries measurable biological cost: within 7 months of the last dose, serum C-telopeptide (a bone resorption marker) returns to pretreatment levels. [2] Keeping coverage continuous is not merely a billing convenience. It is the mechanism through which the drug's anti-fracture benefit is maintained.